Baxter International consensus picture on Wall Street, shares trade steadily on NYSE
30.06.2026 - 11:36:28 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 11:36.
Baxter International (US0673431090) enters Tuesday trading with a stable presence on the NYSE and a well-followed analyst consensus on its shares. The focus for many investors is how upcoming quarterly figures might confirm or challenge those expectations.
What analysts broadly expect
Wall Street coverage of Baxter International centers on its recurring revenue from hospital products and services, with several major brokers rating the stock around neutral to moderately positive based on recent results. Consensus models typically assume mid-single-digit revenue growth and a focus on margin stability over aggressive expansion.
Across the large research houses, estimates for the next earnings release generally cluster around modest year-on-year growth in core segments such as medication delivery and renal care. Many models factor in health system budget pressures but still assume relatively resilient demand for Baxter's portfolio.
The Tuesday focus on consensus
On a Tuesday, investors tend to compare Baxter International with peers like Becton Dickinson or Medtronic to see whether the rating distribution and target ranges imply underperformance or parity. In most recent surveys, Baxter appears positioned in the middle of its peer group, neither strongly favored nor broadly avoided.
The key numbers in these consensus tables include expected earnings per share, revenue trajectory and assumed free cash flow, which guide institutional allocation decisions. Baxter’s steady NYSE listing and its presence in major healthcare indices make it a regular component of diversified sector portfolios.
Background and price data on Baxter International
Further news, quotes and analysis on Baxter International can be found in the dedicated topic section and on the company’s investor-relations pages.
The product behind the stock
Baxter International generates most of its revenue from hospital and clinical products, including intravenous solutions, infusion systems and devices used in medication delivery. The company also offers renal therapies and other critical-care equipment that support treatment for patients with severe and chronic conditions.
Where the stock trades today
The Baxter International shares (US0673431090) trade on 2026-06-30, 11:36 on the NYSE at an indicative level in US dollars consistent with typical recent ranges, with the exact price subject to live market updates.
Key data on the Baxter International shares
- Company: Baxter International Inc.
- ISIN: US0673431090
- WKN: 853647
- Ticker: BAX
- Trading venue: NYSE
- Price (as of 2026-06-30, 11:36): live intraday quotation in USD
- Market cap: latest available figure in USD (as of 2026-06-30)
- Sector / industry: Health Care Equipment & Supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell securities. All data are based on publicly available information believed to be reliable at the time of writing but may change without notice.
